Cargando…
Lactoferrin as potential preventative and adjunct treatment for COVID-19
The coronavirus disease 2019 (COVID-19) pandemic is rapidly advancing across the globe despite drastic public and personal health measures. Antivirals and nutritional supplements have been proposed as potentially useful against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd and International Society of Antimicrobial Chemotherapy.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7390755/ https://www.ncbi.nlm.nih.gov/pubmed/32738305 http://dx.doi.org/10.1016/j.ijantimicag.2020.106118 |
_version_ | 1783564506709884928 |
---|---|
author | Chang, Raymond Ng, Tzi Bun Sun, Wei-Zen |
author_facet | Chang, Raymond Ng, Tzi Bun Sun, Wei-Zen |
author_sort | Chang, Raymond |
collection | PubMed |
description | The coronavirus disease 2019 (COVID-19) pandemic is rapidly advancing across the globe despite drastic public and personal health measures. Antivirals and nutritional supplements have been proposed as potentially useful against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel coronavirus that causes COVID-19, but few have been clinically established. Lactoferrin (Lf) is a naturally occurring, non-toxic glycoprotein that is orally available as a nutritional supplement and has established in vitro antiviral efficacy against a wide range of viruses, including SARS-CoV, a closely related coronavirus to SARS-CoV-2. Furthermore, Lf possesses unique immunomodulatory and anti-inflammatory effects that may be especially relevant to the pathophysiology of severe COVID-19 cases. Here we review the underlying biological mechanisms of Lf as an antiviral and immune regulator, and propose its unique potential as a preventative and adjunct treatment for COVID-19. We hope that further research and development of Lf nutritional supplementation would establish its role for COVID-19. |
format | Online Article Text |
id | pubmed-7390755 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier Ltd and International Society of Antimicrobial Chemotherapy. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73907552020-07-30 Lactoferrin as potential preventative and adjunct treatment for COVID-19 Chang, Raymond Ng, Tzi Bun Sun, Wei-Zen Int J Antimicrob Agents Article The coronavirus disease 2019 (COVID-19) pandemic is rapidly advancing across the globe despite drastic public and personal health measures. Antivirals and nutritional supplements have been proposed as potentially useful against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel coronavirus that causes COVID-19, but few have been clinically established. Lactoferrin (Lf) is a naturally occurring, non-toxic glycoprotein that is orally available as a nutritional supplement and has established in vitro antiviral efficacy against a wide range of viruses, including SARS-CoV, a closely related coronavirus to SARS-CoV-2. Furthermore, Lf possesses unique immunomodulatory and anti-inflammatory effects that may be especially relevant to the pathophysiology of severe COVID-19 cases. Here we review the underlying biological mechanisms of Lf as an antiviral and immune regulator, and propose its unique potential as a preventative and adjunct treatment for COVID-19. We hope that further research and development of Lf nutritional supplementation would establish its role for COVID-19. Elsevier Ltd and International Society of Antimicrobial Chemotherapy. 2020-09 2020-07-30 /pmc/articles/PMC7390755/ /pubmed/32738305 http://dx.doi.org/10.1016/j.ijantimicag.2020.106118 Text en © 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Chang, Raymond Ng, Tzi Bun Sun, Wei-Zen Lactoferrin as potential preventative and adjunct treatment for COVID-19 |
title | Lactoferrin as potential preventative and adjunct treatment for COVID-19 |
title_full | Lactoferrin as potential preventative and adjunct treatment for COVID-19 |
title_fullStr | Lactoferrin as potential preventative and adjunct treatment for COVID-19 |
title_full_unstemmed | Lactoferrin as potential preventative and adjunct treatment for COVID-19 |
title_short | Lactoferrin as potential preventative and adjunct treatment for COVID-19 |
title_sort | lactoferrin as potential preventative and adjunct treatment for covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7390755/ https://www.ncbi.nlm.nih.gov/pubmed/32738305 http://dx.doi.org/10.1016/j.ijantimicag.2020.106118 |
work_keys_str_mv | AT changraymond lactoferrinaspotentialpreventativeandadjuncttreatmentforcovid19 AT ngtzibun lactoferrinaspotentialpreventativeandadjuncttreatmentforcovid19 AT sunweizen lactoferrinaspotentialpreventativeandadjuncttreatmentforcovid19 |